Treatment of Parkinson's Disease in Pregnancy

When a female patient with Parkinson's disease becomes pregnant, treatment decisions require careful reassessment. Standard dopaminergic agents carry varying levels of risk, and the clinical approach must balance effective motor management against fetal safety.

Clinical scenario: Female patient with Parkinson's disease during pregnancy — a situation requiring review of which therapeutic options remain appropriate and which are contraindicated or should be avoided.

Treatment approach — partial overview

When dopaminergic treatment is required during pregnancy, one specific combination is considered appropriate — while several other agent classes commonly used in Parkinson's disease are either contraindicated or must be avoided in this setting. The full protocol specifies the safe option, the agents to avoid, and the clinical rationale for each.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1186/s42466-024-00325-4

Levodopa combined with Carbidopa should be considered if dopaminergic treatment is required during pregnancy.
Medication with dopamine agonists or MAO-B inhibitors should be avoided during pregnancy due to insufficient data.
Amantadine and the decarboxylase inhibitor Benserazide are contraindicated.

View source ↗